'Regulatory delay is a hidden tax on innovation.' Discuss in the context of recent Indian health-sector regulatory reforms (Medical Devices Rules, NDCT Rules).

Regulatory delay imposes no visible levy, yet it consumes an innovator's scarcest assets — time and capital. In health-sector regulation, where approval clocks run into months, India's recent rule amendments treat compressed timelines as a growth instrument without diluting safety.

How delay operates as a hidden tax

• Carrying cost of waiting: capital stays locked in unsold inventory and idle plant while files move; for pharma, prior-permission requirements added months to the drug development cycle before recent easing [2].
• Volume amplifies the burden: CDSCO processes roughly 30,000–35,000 test licence applications annually, so even small per-file delays aggregate into a large systemic cost [2].
• Deterrence effect: uncertain timelines discourage smaller firms from entering high-risk device segments, entrenching import dependence.

Reforms compressing the clock

• Medical Devices Rules, 2017 (draft amendment): manufacturing licence timeline for high-risk Class C and D devices — cardiac stents, hip and knee implants — proposed to fall from 105 to 90 days, with defined stage-wise timelines for scrutiny, notified-body audit, compliance verification and issuance [1].
• NDCT Rules, 2019 amendments (2025): test licence for non-commercial manufacture replaced by prior intimation, saving a minimum of 90 days; residual test-licence processing cut from 90 to 45 days; low-risk BA/BE studies allowed on online intimation [2].
• Risk-proportionate design: the four-class A–D framework already reserves the heaviest scrutiny for high-risk devices, with State authorities licensing Class A and B [3][4].

The countervailing caution Speed cannot substitute for capacity. Shorter statutory clocks demand adequate CDSCO staffing and credible notified bodies; otherwise timelines are met on paper while post-market surveillance weakens. Both notifications therefore retain quality, safety and performance obligations intact [1].

Regulatory time is thus a real cost that policy can lower by design rather than by dilution. Paired with the Cabinet-approved Policy for the Medical Devices Sector [5], predictable timelines plus strengthened regulatory capacity can convert ease of doing business into genuine innovation capability — advancing both Atmanirbhar manufacturing and the citizen's right to affordable, quality-assured care.